Melatonina
Anno: 1999
-
Riferimento:FASEB J. 1999 May;13(8):857-68.Azione della melatonina:Melatonin interferes with the activation of estrogen receptor by estradiol.Target:Estrogen receptor DNA.
-
Riferimento:J Pineal Res. 1999 Jan;26(1):1-8.Azione della melatonina:Melatonin may have a role in the regulation of peripheral blood cell counts.Target:Serum melatonin/circadian rhythms.
-
Riferimento:J Pineal Res. 1999 Mar;26(2):65-100. Review.Azione della melatonina:Decreased melatonin production leads to increased risk of breast cancer.Target:Light at night/electromagnetic fields (EMF).
-
Riferimento:Biol Signals Recept. 1999 Jan-Apr;8(1-2):75-8.Azione della melatonina:Melatonin may influence the proliferation of tumor cells via RZR/ROR receptors.Target:CGP 52608 ligand for RZR/ROR receptors.
Anno: 2000
-
Titolo: Melatonin, experimental basis for a possible application in breast cancer prevention and treatmentRiferimento:Histol Histopathol. 2000 Apr;15(2):637-47. Review.Azione della melatonina:Melatonin (1nM) actions support a possible usefulness in the prevention and treatment of mammary gland malignancy.Target:Inhibit in vitro proliferation of MCF-7.
-
Riferimento:Br J Cancer. 2001 Feb 2;84(3):397-9.Azione della melatonina:Our findings give support to the 'melatonin hypothesis'.Target:Visually impaired women.
-
Riferimento:J Natl Cancer Inst. 2000 May 3;92(9):686-9.Azione della melatonina:Melatonin may act as an antioxidant that can scavenge free radicals and protect against DNA damage.Target:Reduce chemotherapy toxicity.
-
Riferimento:Life Sci. 2000 Nov 3;67(24):2953-60.Azione della melatonina:Melatonin (10(-8)-10(-10) M) may be an inhibitor of human mammary and ovarian carcinoma.Target:Pineal substances shown tumor inhibiting activity.
-
Riferimento:Front Neuroendocrinol. 2000 Apr;21(2):133-70. Review.Azione della melatonina:The small number of clinical studies focusing on the possible therapeutic value of melatonin (1nM) on breast cancer is surprising.Target:Melatonin's antitumoral actions.
-
Titolo: Influence of radiotherapy on 6-sulphatoxymelatonin levels in the urine of brain cancer patients.Riferimento:Neuro Endocrinol Lett. 2000;21(3):203-207.Azione della melatonina:Wide variation in the mean concentration of aMT6S excreted in the urine.Target:6-sulphatoxymelatonin